Key facts
- Lucis Life’s last known valuation is $77.5M (Dec 2025).
- It has raised $9.0M; the latest was Early Stage VC ($8.5M) in Dec 2025.
- Notable investors include Y Combinator, General Catalyst, Kima Ventures, Rebel Fund, Motier Ventures — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Lucis Life
- ·The full record, as it builds
Funding rounds
No funding rounds for Lucis Life are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lucis Life
Developer of a blood testing platform intended to transform regular blood testing into actionable insights to help people live healthier. The company's platform combines medical expertise and artificial intelligence to offer personalized health scores and lifestyle guidance, enabling customers to get a customized health plan tailored to their health status.
- Sector
- Healthcare
- HQ
- Artannes-sur-Indre, France
- Founded
- 2024
- Employees
- 3
- Website
- lucis.life/
- Ownership
- Privately Held (backing)
Lucis Life doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lucis Life shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lucis Life in its N-PORT filings yet. We sweep new filings monthly.